Filtered By:
Condition: Heart Failure
Drug: Diovan
This page shows you your search results in order of relevance. This is page number 4.
Order by Relevance | Date
Total 48 results found since Jan 2013.
The initial timing and dosage pattern of sacubitril/valsartan in patients with acute myocardial infarction undergoing percutaneous coronary intervention
CONCLUSIONS: Early use or high dosage of sacubitril/valsartan medication is associated with an improvement in clinical outcome. The low dose of sacubitril/valsartan is well tolerated and may be an acceptable alternative strategy.PMID:36990878 | DOI:10.1016/j.ejim.2023.03.019
Source: European Journal of Internal Medicine - March 29, 2023 Category: Internal Medicine Authors: Jun Gu Yue Wang Chang-Qian Wang Jun-Feng Zhang Source Type: research
Angiotensin Receptor –Neprilysin Inhibitor Effects on Atherosclerotic Cardiovascular Disease Events: A Meta-Analysis of Randomized Controlled Trials
Sacubitril-valsartan is an angiotensin receptor –neprilysin inhibitor (ARNI) associated with a decreased risk of death and hospitalization for selected patients with heart failure (HF). However, its association with improved atherosclerotic cardiovascular disease (ASCVD) events remains unclear. We performed a meta-analysis to evaluate the assoc iation of ARNI with ASCVD events in patients with HF. We systematically searched PubMed, Embase, Cochrane, and ClinicalTrials.gov for studies comparing ARNIs with angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) in terms of myocardial infarc...
Source: The American Journal of Cardiology - August 22, 2023 Category: Cardiology Authors: Lis Victoria Ravani, Douglas Mesadri Gewehr, Pedro Calomeni, Mateus de Miranda Gauza, Jussara Pereira, Rhanderson Cardoso, Henrique Barbosa Ribeiro, Edimar Bocchi Source Type: research
